Search

Your search keyword '"Rudaitis, Vilius"' showing total 122 results

Search Constraints

Start Over You searched for: Author "Rudaitis, Vilius" Remove constraint Author: "Rudaitis, Vilius"
122 results on '"Rudaitis, Vilius"'

Search Results

1. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

2. Analysis of Predictive Factors Associated with Unsuccessful Sentinel Lymph Node Mapping in Endometrial Carcinoma.

3. The association between sonographic features and clinical symptoms of adenomyosis.

4. An Ovarian Sertoli–Leydig Cell Tumor with Elevated Alpha-Fetoprotein in an Adolescent: A Rare Case Report and Literature Review.

6. Expression Patterns of Cytokeratins (CK7, CK20, CK19, CK AE1/AE3) in Atypical Endometrial Hyperplasia Coexisting with Endometrial Cancer.

11. Multidisciplinary Implementation of the First VERSIUS Robotic Surgical System in the Baltic Countries.

16. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis

18. Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe

24. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

25. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

28. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.

29. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

30. The FANCM :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

31. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

32. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

33. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

36. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

37. Išplitusio kiaušidžių vėžio BRCA1/2 genų mutacijų įvairovė ir jų prognozinė reikšmė ligos berecidyviam ir bendrajam pacienčių išgyvenamumui

38. BRCA1/2 mutation spectrum and its prognostic significance for progression-free and overall survival in advanced ovarian cancer

41. Histological evaluation of cervical oncocytology and cone biopsy value in the treatment of cervical pathology

42. ATL

43. Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe

45. BRCA1/2 Mutation Status Is an Independent Factor of Improved Survival for Advanced (Stage III-IV) Ovarian Cancer.

46. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

47. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

48. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

49. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

50. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Catalog

Books, media, physical & digital resources